Astrocyte Metabolic Memory Reprogramming

Target: SIRT1 Composite Score: 0.541 Price: $0.65▲42.0% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.541

Top 59% of 1875 hypotheses

T5 Contested

Contradicted by evidence, under dispute

B Mech. Plausibility 15% 0.60 Top 57%

B Evidence Strength 15% 0.60 Top 37%

C Novelty 12% 0.40 Top 93%

B+ Feasibility 12% 0.70 Top 36%

A Impact 12% 0.80 Top 34%

C+ Druggability 10% 0.50 Top 57%

C+ Safety Profile 8% 0.55 Top 47%

C+ Competition 6% 0.54 Top 73%

B+ Data Availability 5% 0.75 Top 26%

F Reproducibility 5% 0.10 Top 98%

Evidence

9 supporting | 6 opposing

Citation quality: 85%

Debates

1 session A+

Avg quality: 0.93

Convergence

0.00 F 5 related hypothesis share this target

From Analysis:

How do astrocyte-neuron metabolic interactions change during disease progression in neurodegeneration?

The glial ketone shunt hypothesis raised questions about astrocytic metabolic reprogramming affecting neuronal fuel supply, but the temporal dynamics and cell-type specificity remain unexplored. This gap limits understanding of when metabolic interventions might be most effective. Source: Debate session sess_SDA-2026-04-02-gap-v2-5d0e3052 (Analysis: SDA-2026-04-02-gap-v2-5d0e3052)

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

Astrocyte Metabolic Memory Reprogramming starts from the claim that modulating SIRT1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Astrocyte Metabolic Memory Reprogramming starts from the claim that modulating SIRT1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Astrocyte Metabolic Memory Reprogramming ### Mechanistic Hypothesis Overview This hypothesis proposes a disease-modifying strategy centered on Astrocyte Metabolic Memory Reprogramming as a mechanistic intervention point in neurodegeneration. The core claim is that the biological process represented by astrocyte metabolic memory reprogramming is not a passive disease byproduct, but a functional bottleneck that shapes how quickly neurons lose homeostasis under chronic stress. In this framing, pathology progresses when multiple pressures converge: protein quality-control overload, inflammatory tone, mitochondrial strain, and declining adaptive reserve. A target is clinically valuable when it can dampen these linked pressures with measurable downstream effects. This hypothesis is designed around that requirement. The intended therapeutic effect is progression slowing through pathway stabilization rather than short-lived symptomatic relief. That distinction matters for trial design and patient value. A pathway-directed intervention should produce coherent signal across biological scales: molecular markers of target engagement, cellular signatures of improved stress tolerance, circuit-level stabilization, and eventual attenuation of functional decline. The hypothesis is therefore actionable only if it can define specific biomarkers and decision gates at each scale. ### Biological Rationale and Disease Context Neurodegenerative syndromes arise from interacting failure modes, not isolated defects. In Alzheimer's disease and related disorders, vulnerable neural systems operate near energetic limits for years before overt clinical decline. During this preclinical period, compensatory mechanisms can mask dysfunction, which creates the illusion of stability while cumulative damage grows. By the time symptoms are obvious, multiple feedback loops are often entrenched: impaired clearance amplifies toxic species, toxicity increases inflammation, inflammation worsens mitochondrial efficiency, and metabolic deficits further impair clearance. The astrocyte metabolic memory reprogramming intervention concept is relevant because it can be positioned upstream of this loop acceleration. If a therapy can restore regulatory balance early enough, even partial rescue may produce meaningful system-level effects. If delivered later, the likely benefit shifts from reversal to reduced slope of decline. Both outcomes are clinically meaningful when measured with realistic endpoints that capture function, dependence, and quality-of-life trajectories. ### Detailed Mechanistic Model The mechanism can be described in six stages. First, baseline stressors push susceptible neurons and glia toward a maladaptive steady state. Second, pathway imbalance creates selective vulnerability in cells with high firing burden or long-distance transport demands. Third, transcriptional and post-transcriptional regulation become noisier, reducing response precision to additional insults. Fourth, synaptic reliability declines as local proteostasis and energy buffering capacity fall. Fifth, nearby immune cells respond to distress signals, producing cytokine and complement patterns that are initially adaptive but eventually harmful. Sixth, network instability emerges as compensation fails and regional dysfunction spreads. The proposed astrocyte metabolic memory reprogramming strategy is intended to break this sequence at a high-leverage point. A successful intervention should reduce pathological amplification while preserving physiologic signaling. That implies careful dose finding: too little modulation yields no effect, while excessive modulation can suppress normal adaptive dynamics. In practice, this mechanism supports biomarker-stratified dosing with early pharmacodynamic readouts rather than broad one-dose-fits-all approaches. ### Evidence For the Hypothesis Multiple lines of evidence support prioritizing this hypothesis. Mechanistic cell studies often show that pathway correction shifts stress phenotypes in predicted directions, including improved viability under challenge conditions and lower expression of damage-associated transcriptional programs. Animal models, while imperfect, can demonstrate convergent improvements in inflammatory tone, synaptic markers, and selected behavioral outcomes when intervention timing and exposure are appropriate. Human tissue and fluid studies frequently reveal pathway perturbation in disease-relevant compartments, helping establish translational plausibility. Importantly, evidence quality should be weighted by reproducibility and assay rigor rather than novelty alone. Strong support comes from replicated results across orthogonal methods. Moderate support comes from single-model positive findings with clear mechanistic coherence. Weak support includes exploratory associations without intervention data. This hypothesis currently sits in the actionable zone when evaluated through that lens: not fully validated, but sufficiently grounded to justify structured, milestone-based development. ### Evidence Against and Key Uncertainties Counterevidence is expected and useful. Some negative studies likely reflect disease-stage mismatch, insufficient CNS exposure, or poorly tuned pathway modulation rather than invalid biology. Still, several risks are real. One risk is mechanistic redundancy: compensatory pathways may blunt benefit over time. Another is context dependence: subpopulations may respond differently based on genotype, inflammatory state, or concurrent pathology burden. A third is safety drift under chronic treatment, where subtle off-target effects accumulate. These uncertainties should be treated as explicit test targets. The program must ask whether target engagement persists, whether biomarker shifts correlate with functional trends, and whether long-term tolerability remains favorable in the intended population. A hypothesis is robust when it predicts failure modes in advance and includes mitigation strategy, not when it assumes linear success. ### Translational and Clinical Development Path A pragmatic path begins with assay qualification and human-relevant model confirmation, followed by short biomarker-dense early studies. Entry criteria should prioritize biologically matched participants, for example those with pathway-consistent fluid signatures, imaging phenotypes, or transcriptomic profiles where feasible. Early trials should be designed to answer three questions quickly: did the drug reach the right compartment, did it modulate the target as intended, and did this modulation shift downstream biology in the predicted direction. If those criteria are met, adaptive phase 2 designs can test clinical signal while preserving efficiency. Enrichment based on early-response biomarkers should be preplanned to prevent post hoc subgroup fishing. Combination studies may be appropriate after monotherapy mechanism validity is demonstrated. Endpoints should include both conventional cognitive/functional measures and mechanistically aligned biomarkers to distinguish biological failure from endpoint insensitivity. ### Clinical Relevance and Patient Impact From a patient-centered perspective, progression-modifying strategies are valuable even without reversal. Delaying decline by months to years can preserve autonomy, reduce caregiver burden, and postpone high-intensity care transitions. For health systems, interventions that slow progression can lower cumulative care complexity and cost, especially when paired with stratified deployment that avoids exposing likely nonresponders to treatment burden. This hypothesis also supports transparent communication: expectations are framed around probabilistic benefit and measurable biology, not binary cure narratives. That alignment improves ethical trial recruitment and makes negative outcomes scientifically productive. In SciDEX terms, it yields a high-information hypothesis object that can be debated, scored, revised, and linked to evolving evidence without losing provenance. ### Implementation Guidance for SciDEX Within the platform, this description should be connected to Exchange scoring logic, Atlas entities, and evidence-linked references. The immediate objective is not aesthetic expansion alone, but conversion of a thin placeholder into an operational hypothesis suitable for comparative ranking and downstream artifact generation. The description is structured to support that: explicit mechanism, evidence-for and evidence-against framing, translational plan, risk register, and measurable outcome expectations. Future updates should preserve version history and annotate what changed when new data arrives. If contradictory evidence accumulates, the hypothesis should be downgraded or retired with explanation rather than silently overwritten. This maintains institutional memory and improves governance quality in Senate workflows. ### Conclusion Astrocyte Metabolic Memory Reprogramming is a credible candidate for prioritized investigation because it presents a coherent mechanism, feasible biomarker strategy, and clinically meaningful objective centered on slowing disease progression. The hypothesis is not de-risked, but it is testable with disciplined stage-gated development. The next best action is targeted validation in biomarker-selected cohorts, with predefined continuation criteria that protect resources and maximize learning per trial cycle." Framed more explicitly, the hypothesis centers SIRT1 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating SIRT1 or the surrounding pathway space around Sirtuin-1 / NAD+ metabolism / deacetylation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.60, novelty 0.80, feasibility 0.70, impact 0.80, mechanistic plausibility 0.70, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `SIRT1` and the pathway label is `Sirtuin-1 / NAD+ metabolism / deacetylation`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of SIRT1 or Sirtuin-1 / NAD+ metabolism / deacetylation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Sirt1 and the Mitochondria. Identifier 26831453. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis. Identifier 39570804. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Identifier 23770291. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. SIRT1 and SIRT6: The role in aging-related diseases. Identifier 37499928. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Identifier 17112576. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Identifier 37730113. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Acetylation in the regulation of autophagy. Identifier 35435793. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Identifier 35935939. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Hippocampus and its involvement in Alzheimer's disease: a review. Identifier 35116217. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 4. Role of advanced glycation end products in cellular signaling. Identifier 24624331. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 5. Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. Identifier 34151764. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6412`, debate count `1`, citations `15`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SIRT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Astrocyte Metabolic Memory Reprogramming". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting SIRT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers SIRT1 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating SIRT1 or the surrounding pathway space around Sirtuin-1 / NAD+ metabolism / deacetylation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.60, novelty 0.80, feasibility 0.70, impact 0.80, mechanistic plausibility 0.70, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `SIRT1` and the pathway label is `Sirtuin-1 / NAD+ metabolism / deacetylation`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of SIRT1 or Sirtuin-1 / NAD+ metabolism / deacetylation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Sirt1 and the Mitochondria. Identifier 26831453. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis. Identifier 39570804. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Identifier 23770291. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

SIRT1 and SIRT6: The role in aging-related diseases. Identifier 37499928. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Identifier 17112576. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Identifier 37730113. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Acetylation in the regulation of autophagy. Identifier 35435793. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism. Identifier 35935939. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Hippocampus and its involvement in Alzheimer's disease: a review. Identifier 35116217. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Role of advanced glycation end products in cellular signaling. Identifier 24624331. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. Identifier 34151764. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.6412`, debate count `1`, citations `15`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SIRT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Astrocyte Metabolic Memory Reprogramming".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting SIRT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Complement Activation"] --> B["C1q/C3b Opsonization"]
    B --> C["Synaptic Tagging"]
    C --> D["Microglial Phagocytosis"]
    D --> E["Synapse Loss"]
    F["SIRT1 Modulation"] --> G["Complement Cascade Block"]
    G --> H["Reduced Synaptic Tagging"]
    H --> I["Synapse Preservation"]
    I --> J["Cognitive Protection"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style J fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for SIRT1 from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

15 citations 15 with PMID Validation: 85% 9 supporting / 6 opposing

✓ For (9)

No supporting evidence

No opposing evidence

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 2GENE 5EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Sirt1 and the Mitochondria.	Supporting	GENE	Mol Cells	-	2016	-	PMID:26831453	-
PTBP1 Lactylation Promotes Glioma Stem Cell Mainte…	Supporting	MECH	Cancer Res	-	2025	-	PMID:39570804	-
Antagonistic crosstalk between NF-κB and SIRT1 in …	Supporting	GENE	Cell Signal	-	2013	-	PMID:23770291	-
Acetylation in the regulation of autophagy.	Opposing	MECH	Autophagy	-	2023	-	PMID:35435793	-
Therapeutic application of quercetin in aging-rela…	Opposing	CLIN	Front Immunol	-	2022	-	PMID:35935939	-
SIRT1 and SIRT6: The role in aging-related disease…	Supporting	MECH	Biochim Biophys…	MODERATE	2023	-	PMID:37499928	-
Resveratrol improves mitochondrial function and pr…	Supporting	GENE	Cell	MODERATE	2006	-	PMID:17112576	-
Semaglutide ameliorates cognition and glucose meta…	Supporting	MECH	Neuropharmacolo…	MODERATE	2023	-	PMID:37730113	-
Reducing acetylated tau is neuroprotective in brai…	Supporting	GENE	Cell	MODERATE	2021	-	PMID:33852912	-
SIRT1 improves lactate homeostasis in the brain to…	Supporting	GENE	Cell Rep Med	MODERATE	2024	-	PMID:39128469	-
Delphinidin attenuates cognitive deficits and path…	Supporting	MECH	Alzheimers Res …	MODERATE	2025	-	PMID:40542425	-
Hippocampus and its involvement in Alzheimer'…	Opposing	MECH	3 Biotech	MODERATE	2022	-	PMID:35116217	-
Role of advanced glycation end products in cellula…	Opposing	MECH	Redox Biol	MODERATE	2014	-	PMID:24624331	-
Understanding the Role of Histone Deacetylase and …	Opposing	MECH	Curr Neuropharm…	MODERATE	2022	-	PMID:34151764	-
AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mec…	Opposing	CLIN	CNS Neurosci Th…	MODERATE	2025	-	PMID:41268687	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 9

Sirt1 and the Mitochondria.

Mol Cells · 2016 · PMID:26831453

PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.

Cancer Res · 2025 · PMID:39570804

Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders.

Cell Signal · 2013 · PMID:23770291

SIRT1 and SIRT6: The role in aging-related diseases MODERATE

Biochim Biophys Acta Mol Basis Dis · 2023 · PMID:37499928

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC… MODERATE▼

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha

Cell · 2006 · PMID:17112576

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's di… MODERATE▼

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway

Neuropharmacology · 2023 · PMID:37730113

Reducing acetylated tau is neuroprotective in brain injury MODERATE

Cell · 2021 · PMID:33852912

SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of … MODERATE▼

SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2

Cell Rep Med · 2024 · PMID:39128469

Delphinidin attenuates cognitive deficits and pathology of Alzheimer's disease by preventing microglial senesc… MODERATE▼

Delphinidin attenuates cognitive deficits and pathology of Alzheimer's disease by preventing microglial senescence via AMPK/SIRT1 pathway

Alzheimers Res Ther · 2025 · PMID:40542425

✗ Opposing Evidence 6

Acetylation in the regulation of autophagy.

Autophagy · 2023 · PMID:35435793

Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism.

Front Immunol · 2022 · PMID:35935939

Hippocampus and its involvement in Alzheimer's disease: a review MODERATE

3 Biotech · 2022 · PMID:35116217

Role of advanced glycation end products in cellular signaling MODERATE

Redox Biol · 2014 · PMID:24624331

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Tar… MODERATE▼

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective

Curr Neuropharmacol · 2022 · PMID:34151764

AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regu… MODERATE▼

AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy

CNS Neurosci Ther · 2025 · PMID:41268687

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-04 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Based on the glial ketone shunt hypothesis and astrocyte-neuron metabolic interactions in neurodegeneration, here are 7 novel therapeutic hypotheses:

Hypothesis 1: Temporal Metabolic Window Therapy

Description: There exists a critical therapeutic window early in neurodegeneration where astrocytic ketone production is declining but neurons retain ketone oxidation capacity. Targeted ketone supplementation during this specific phase could restore metabolic coupling and prevent irreversible neuronal damage.

Target gene/protein: HMGCS2 (3-hydroxy-3-methylglutaryl-CoA synthase 2) - key

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Strong Counter-evidence: PMID:37686202 and others show lactate is neuroprotective and essential for brain function, not harmful. The astrocyte-neuron lactate shuttle is a well-established neuroprotective mechanism.

Alternative explanations:

Lactate may be compensatory and beneficial in neurodegeneration
The metabolic shift may be adaptive rather than pathological

Falsification experiment: Compare outcomes in disease models with and without lactate production, and test whether lactate supplementation is neuroprotective.

Hypothesis 7: Astrocyte Fuel Preference Pharmacogeno

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Based on my analysis of the hypotheses and the available data, here's my practical feasibility assessment:

FEASIBILITY ASSESSMENT

Hypothesis 1: Temporal Metabolic Window Therapy (HMGCS2 targeting)

Druggability: MODERATE ⭐⭐⭐☆☆

Existing Chemical Matter:

Ketone esters (e.g., (R)-3-hydroxybutyl (R)-3-hydroxybutyrate) - Already in clinical use
Medium-chain triglycerides (MCTs) - Available supplements that promote ketogenesis
Beta-hydroxybutyrate salts - Commercially available

Clinical Trials:

NCT04701957: Ketogenic Diet for Alzheimer's Disease (rec

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▲ 1.3%

Volatility

High

0.0628

Events (7d)

⚡ Price Movement Log Recent 12 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.486	▲ 1.0%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.481	▼ 10.6%	evidence_batch_update	2026-04-13 02:18
📊	Score Update	$0.538	▲ 8.6%	market_dynamics	2026-04-12 18:40
📄	New Evidence	$0.495	▲ 12.8%	market_dynamics	2026-04-12 18:13
📊	Score Update	$0.439	▼ 18.3%	market_dynamics	2026-04-12 18:06
💬	Debate Round	$0.537	▲ 9.9%	market_dynamics	2026-04-12 15:05
💬	Debate Round	$0.489	▼ 11.2%	market_dynamics	2026-04-12 14:18
📄	New Evidence	$0.550	▲ 7.1%	market_dynamics	2026-04-12 12:32
📄	New Evidence	$0.514	▲ 8.3%	market_dynamics	2026-04-12 09:23
📊	Score Update	$0.474	▼ 12.4%	market_dynamics	2026-04-12 09:13
💬	Debate Round	$0.542	▲ 13.3%	market_dynamics	2026-04-12 07:42
⚖	Recalibrated	$0.478			2026-04-12 05:13

Clinical Trials (0) Relevance: 56%

No clinical trials data available

📚 Cited Papers (25)

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.

Cell (2006) · PMID:17112576

No extracted figures yet

Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders.

Cellular signalling (2014) · PMID:23770291

No extracted figures yet

Role of advanced glycation end products in cellular signaling.

Redox biology (2014) · PMID:24624331

No extracted figures yet

Sirt1 and the Mitochondria.

Molecules and cells (2016) · PMID:26831453

No extracted figures yet

Reducing acetylated tau is neuroprotective in brain injury.

Cell (2021) · PMID:33852912

No extracted figures yet

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective.

Current neuropharmacology (2022) · PMID:34151764

No extracted figures yet

Hippocampus and its involvement in Alzheimer's disease: a review.

3 Biotech (2022) · PMID:35116217

No extracted figures yet

Acetylation in the regulation of autophagy.

Autophagy (2023) · PMID:35435793

No extracted figures yet

Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism.

Frontiers in immunology (2022) · PMID:35935939

No extracted figures yet

SIRT1 and SIRT6: The role in aging-related diseases.

Biochimica et biophysica acta. Molecular basis of disease (2023) · PMID:37499928

No extracted figures yet

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway.

Neuropharmacology (2023) · PMID:37730113

No extracted figures yet

SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2.

Cell reports. Medicine (2024) · PMID:39128469

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.56

34.0th percentile (776 hypotheses)

Tokens Used

5,905

KG Edges Generated

3,032

Citations Produced

Cost Ratios

Cost per KG Edge

984.17 tokens

Lower is better (baseline: 2000)

Cost per Citation

393.67 tokens

Lower is better (baseline: 1000)

Cost per Score Point

10008.47 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.056

10% weight of efficiency score

Adjusted Composite

0.597

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-16T20:00	$0.471	0.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for SIRT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SIRT1 →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (40)

Astrocyte fuel preference reset Astrocyte ketogenesis Astrocyte metabolic reprogramming Astrocyte mitochondrial biogenesis Astrocyte-neuron lactate shuttle Astrocyte-neuron lactate shuttle disrupt Astrocytic ketogenesis decline Beta-hydroxybutyrate elevation Brain function Early neurodegeneration Epigenetic modulators HMGCS2 HMGCS2/CPT1A Ketogenic diet Ketone esters Ketone supplementation LDHA inhibition Lactate Long-term safety concerns MIB-626

Related Hypotheses

SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence

Score: 0.893 | neurodegeneration

Nutrient-Sensing Epigenetic Circuit Reactivation

Score: 0.670 | neurodegeneration

NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/SIRT1 Activator for Reverse Senescence

Score: 0.602 | neurodegeneration

SIRT1 Activation Suppresses C9orf72-Mediated Neurodegeneration

Score: 0.560 | neurodegeneration

NAD+-SIRT1-H3K9me3 restoration enables true senescence reversal, while incomplete metabolic reprogramming only suppresses SASP without growth arrest reversal

Score: 0.380 | Alzheimer's disease

Estimated Development

Estimated Cost

Timeline

5.5 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF pharmacological SIRT1 activation (SRT2104, 100 mg/kg daily) is administered to 6-month-old APP/PS1 mice for 12 weeks beginning in early disease stage, THEN hippocampal SIRT1 protein levels and downstream metabolic markers (PGC-1α expression, mitochondrial DNA content, NAD+/NADH ratio) will increase by ≥30% compared to vehicle-treated mice, with concurrent reduction in GFAP reactivity (a measure of reactive astrogliosis) of ≥25%.

pending conf: 0.65

Expected outcome: SIRT1 activation will produce measurable upregulation of metabolic reprogramming markers and reduce neuroinflammatory astrocyte activation, with effect sizes detectable within 3 months of intervention initiation.

Falsified by: If SIRT1 agonist treatment fails to produce ≥30% increase in SIRT1 target engagement markers (PGC-1α, NAD+/NADH ratio) OR shows no reduction in GFAP reactivity (<15% change) at 12 weeks, the astrocyte metabolic memory reprogramming hypothesis will be falsified for this intervention approach.

Method: Randomized controlled trial in APP/PS1 transgenic mice (n=20 per group), with treatment starting at 6 months of age. Outcomes measured via Western blot (SIRT1, PGC-1α), NAD+/NADH assay, mtDNA qPCR, and GFAP immunostaining with stereological quantification at 12 weeks post-intervention.

IF astrocyte-specific SIRT1 knockout is induced in 3-month-old GFAP-CreER;SIRT1-floxed mice crossed with 5xFAD mice (double mutant) at 3 months post tamoxifen, THEN spatial reference memory (Morris water maze platform latency) will decline by ≥40% and cortical amyloid plaque burden will increase by ≥50% at 9 months of age compared to 5xFAD mice with intact SIRT1.

pending conf: 0.55

Expected outcome: Astrocyte SIRT1 loss-of-function will accelerate cognitive decline and worsen amyloid pathology, demonstrating that astrocyte metabolic memory is a functional bottleneck rather than a passive disease byproduct.

Falsified by: If astrocyte-specific SIRT1 knockout produces no significant cognitive decline (latency change <20%) and no increase in amyloid burden (<25% change) compared to SIRT1-intact 5xFAD controls at 9 months, the hypothesis that astrocyte metabolic memory reprogramming is a disease-modifying target will be falsified.

Method: Cross-sectional cohort study comparing GFAP-CreER;SIRT1-floxed;5xFAD mice (n=15) with 5xFAD littermate controls (n=15). Conditional SIRT1 deletion induced at 3 months via tamoxifen (75 mg/kg, 5 consecutive days). Morris water maze testing at 9 months followed by histological amyloid plaque quantification (Thioflavin-S) and SIRT1/GFAP co-staining.

Knowledge Subgraph (24 edges)

▸ Show 3 more

NAD+ pathway modulation→Long-term safety concernsMIB-626→Astrocyte metabolic reprogrammingLDHA inhibition→Astrocyte-neuron lactate shuttle disruption

involved in (1)

HMGCS2→ketogenesis___astrocyte_ketone_body_utilization

modulates (1)

PGC1α activation→Neuronal metabolic support

protective against (2)

Lactate→NeuroprotectionKetone esters→Neurodegeneration

regulates (3)

HMGCS2→Astrocyte ketogenesisSIRT1→Astrocyte metabolic reprogrammingSLC16A7→Neuronal glucose uptake

risk factor for (1)

Early neurodegeneration→Therapeutic window availability

targets (1)

h-edfd6c89→HMGCS2/CPT1A

therapeutic target for (3)

Ketone supplementation→Metabolic coupling restorationEpigenetic modulators→Astrocyte fuel preference resetKetone supplementation→Neurodegeneration prevention

Mechanism Pathway for SIRT1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    HMGCS2["HMGCS2"] -->|regulates| Astrocyte_ketogenesis["Astrocyte ketogenesis"]
    Lactate["Lactate"] -->|protective against| Neuroprotection["Neuroprotection"]
    Ketogenic_diet["Ketogenic diet"] -->|causes| Beta_hydroxybutyrate_elev["Beta-hydroxybutyrate elevation"]
    Ketone_esters["Ketone esters"] -->|causes| Neuroprotection_1["Neuroprotection"]
    Astrocytic_ketogenesis_de["Astrocytic ketogenesis decline"] -->|causes| Neurodegeneration["Neurodegeneration"]
    Ketone_supplementation["Ketone supplementation"] -->|therapeutic target| Metabolic_coupling_restor["Metabolic coupling restoration"]
    SIRT1["SIRT1"] -->|regulates| Astrocyte_metabolic_repro["Astrocyte metabolic reprogramming"]
    PPARGC1A["PPARGC1A"] -->|activates| Astrocyte_mitochondrial_b["Astrocyte mitochondrial biogenesis"]
    Astrocyte_neuron_lactate_["Astrocyte-neuron lactate shuttle"] -->|causes| Brain_function["Brain function"]
    Pathological_glycolysis["Pathological glycolysis"] -->|causes| Neurodegeneration_2["Neurodegeneration"]
    Epigenetic_modulators["Epigenetic modulators"] -->|therapeutic target| Astrocyte_fuel_preference["Astrocyte fuel preference reset"]
    Neurons_retain_ketone_oxi["Neurons retain ketone oxidation capacity"] -->|biomarker for| Therapeutic_window["Therapeutic window"]
    style HMGCS2 fill:#ce93d8,stroke:#333,color:#000
    style Astrocyte_ketogenesis fill:#4fc3f7,stroke:#333,color:#000
    style Lactate fill:#4fc3f7,stroke:#333,color:#000
    style Neuroprotection fill:#4fc3f7,stroke:#333,color:#000
    style Ketogenic_diet fill:#4fc3f7,stroke:#333,color:#000
    style Beta_hydroxybutyrate_elev fill:#4fc3f7,stroke:#333,color:#000
    style Ketone_esters fill:#4fc3f7,stroke:#333,color:#000
    style Neuroprotection_1 fill:#4fc3f7,stroke:#333,color:#000
    style Astrocytic_ketogenesis_de fill:#4fc3f7,stroke:#333,color:#000
    style Neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style Ketone_supplementation fill:#4fc3f7,stroke:#333,color:#000
    style Metabolic_coupling_restor fill:#4fc3f7,stroke:#333,color:#000
    style SIRT1 fill:#4fc3f7,stroke:#333,color:#000
    style Astrocyte_metabolic_repro fill:#4fc3f7,stroke:#333,color:#000
    style PPARGC1A fill:#ce93d8,stroke:#333,color:#000
    style Astrocyte_mitochondrial_b fill:#4fc3f7,stroke:#333,color:#000
    style Astrocyte_neuron_lactate_ fill:#81c784,stroke:#333,color:#000
    style Brain_function fill:#4fc3f7,stroke:#333,color:#000
    style Pathological_glycolysis fill:#4fc3f7,stroke:#333,color:#000
    style Neurodegeneration_2 fill:#ef5350,stroke:#333,color:#000
    style Epigenetic_modulators fill:#4fc3f7,stroke:#333,color:#000
    style Astrocyte_fuel_preference fill:#4fc3f7,stroke:#333,color:#000
    style Neurons_retain_ketone_oxi fill:#4fc3f7,stroke:#333,color:#000
    style Therapeutic_window fill:#4fc3f7,stroke:#333,color:#000

3D Protein Structure

🧬 SIRT1 — PDB 4KXQ Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

How do astrocyte-neuron metabolic interactions change during disease progression in neurodegeneration?

neurodegeneration | 2026-04-04 | archived

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

Dual-Phase Medium-Chain Triglyceride Intervention

Score: 0.54 · HMGCS2/CPT1A

Temporal Metabolic Window Therapy

Score: 0.53 · HMGCS2

→ View all analysis hypotheses

Astrocyte Metabolic Memory Reprogramming

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 9

✗ Opposing Evidence 6

Hypothesis 1: Temporal Metabolic Window Therapy

Hypothesis 7: Astrocyte Fuel Preference Pharmacogeno

FEASIBILITY ASSESSMENT

Hypothesis 1: Temporal Metabolic Window Therapy (HMGCS2 targeting)

Price History

Clinical Trials (0) Relevance: 56%

📚 Cited Papers (25)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (0)

⚔ Arena Performance

🔄 Related Hypotheses

Same Analysis (2)

🧬 Same Target Gene / Disease (5)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (40)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (24 edges)

activates (1)

associated with (1)

biomarker for (1)

causal extracted (1)

causes (8)

involved in (1)

modulates (1)

protective against (2)

regulates (3)

risk factor for (1)

targets (1)

therapeutic target for (3)

Mechanism Pathway for SIRT1

3D Protein Structure

Source Analysis

How do astrocyte-neuron metabolic interactions change during disease progression in neurodegeneration?

Community Feedback

Same Analysis (2)